Hvad er åbningstiderne?

Mandag 09:00 - 17:30 Tirsdag 09:00 - 17:30 Onsdag 09:00 - 17:30 Torsdag 09:00 - 17:30 Fredag 09:00 - 17:30

RetinaLyze International

Hjem
Danmark
Skovlunde
RetinaLyze International

Rutevejledning Website Kontakt virksomheden

Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine.

04/11/2026

New device integration: Volk VIVA

RetinaLyze now works with the Volk VIVA, the handheld non-mydriatic fundus camera.

The VIVA captures a 45° field through a 3 mm pupil, with nine fixation targets and images in under a minute, and it weighs under a kilogram. Pair it with RetinaLyze and a screening no longer needs a fixed room: capture at the chair, in the pharmacy or on an outreach visit, analyse, and have signs of pathology flagged in about 45 seconds.

What this means for a practice or a chain:
Screening where the patient is. A handheld camera and the analysis in one workflow.
Referral built in. Send a case to an ophthalmologist for a second opinion from wherever you captured it.
The same result everywhere. Objective, reproducible outputs across locations, operators and time.

The AI analyses. You decide. RetinaLyze detects signs of pathology; it does not diagnose and does not replace an examination.

If you use the VIVA today, book a demo and we will set you up: https://retinalyze.com/free-trial/

02/11/2026

Neither of us can tell you what eye care looks like in five years. We asked each other anyway, with no script and no rehearsal.

Sondre Enger Beckröge of EYS went first, and his answer was less dramatic than you might expect. EYS in five years looks a lot like EYS today, only more automated and far more customisable. His image for it: a glove that fits the hand, where every optician can shape their own setup inside the platform, with tools like RetinaLyze built into it rather than bolted on beside it.

Teddy Birch Petersen said much the same about RetinaLyze. We've been at this since 2013, the pace of AI has picked up sharply, and we're building constantly. The direction he's most curious about is what a retinal image can say beyond the eye, where it connects to systemic disease. That's a research direction, not a product.

Where we both landed: the core doesn't get disrupted. AI stays AI. Connectivity stays connectivity. New ways of doing it, same underlying job.

So what's your five-year prediction for eye care?

29/10/2026

New device integration: Optomed Plc Aurora IQ

RetinaLyze now works with the Optomed Aurora IQ, the handheld non-mydriatic fundus camera.

Capture on the Aurora IQ, upload to the RetinaLyze WebApp, and RetinaLyze DR, AMD and Glaucoma investigates the image for potential changes that could indicate early signs of disease. An overlay shows you where they were identified.

The Aurora IQ captures a 50° field without dilation and weighs about half a kilo, so the camera comes to the patient’s chair instead of the patient going to the camera.

What this means for a practice or a chain:
One workflow. Upload images from the Aurora IQ to the RetinaLyze WebApp for analysis and the patient report.

Referral when you need it. Send a case to an ophthalmologist for a second opinion through the telemedicine module.

Image quality still decides the result. A handheld camera is easy to bring to the patient. It also asks more of whoever holds it. If the image isn’t good enough, retake it.

The AI analyses. You decide. RetinaLyze doesn’t diagnose, and it doesn’t replace your examination.

If you use the Aurora IQ today, book a demo and we’ll set you up: https://retinalyze.com/free-trial

26/10/2026

The most common misconception about AI in eye care is that it's there to replace you.

It isn't. That's where Teddy Birch Petersen starts in the fourth film, and he's blunt about why. A human in the loop understands other humans. AI doesn't. What it can do is help professionals reach better decisions faster.

Sondre Enger Beckrøge of Eys agrees, and draws the line clearly: the ophthalmologist, the optometrist or the optician controls the AI, always. Used that way it works as a decision tool, and it takes over the repetitive manual work that nobody particularly enjoys.

The film ends on the part that gets discussed less. Making early detection cheaper and easier to reach matters most in places without the specialists, the staffing or the budgets that most of Western Europe takes for granted.

What's the misconception about AI you hear most often in your own practice?

21/10/2026

New device integration: Optovue iCam

RetinaLyze now works with the Optovue iCam, the compact non-mydriatic fundus camera.

The iCam captures 45° colour and red-free images with simple joystick alignment, and it sits in many practices already, alongside the iVue OCT. Pair it with RetinaLyze and the images you are capturing anyway are checked for signs of pathology in about 45 seconds, with the reasoning shown.

What this means for a practice or a chain:
One workflow. Images move from the iCam into RetinaLyze for analysis and the patient report.
Referral built in. Send a case to an ophthalmologist for a second opinion without leaving the room.
The same result everywhere. Objective, reproducible outputs across locations, operators and time.

The AI analyses. You decide. RetinaLyze detects signs of pathology; it does not diagnose and does not replace an examination.

If you use the iCam today, book a demo and we will set you up: https://retinalyze.com/free-trial/

19/10/2026

A fundus image is captured. What happens next?

That's the question in the third film from our cooperation with EYS. Sondre Enger Beckrøge walks through the actual workflow, and Teddy Birch Petersen asks the follow-ups.

The image goes into Eys. From there you have three routes. Run it through RetinaLyze AI for signs of diabetic retinopathy, AMD and glaucoma. Send it digitally to a doctor for verification, diagnosis or treatment. Or do both: analyse first, then have a doctor verify the result.

The practical difference is that it's now one platform instead of two. Images and patient information get uploaded once, not twice.

Sondre also talks about where this is heading. EYS is working on connecting journal systems and cameras to the same platform, with the goal that analysing an image and sending it onward takes a single click.

Which of the three routes would you use most in your practice?

14/10/2026

New device integration: ZEISS VISUREF 1000

RetinaLyze now works with the ZEISS VISUREF 1000, the screening station that combines refraction, topography, tonometry and pachymetry with 45° non-mydriatic fundus imaging.

The fundus images the VISUREF 1000 captures during the exam go straight into RetinaLyze, so the same visit that measures refraction and pressure also checks the retina for signs of pathology, with the result back in about 45 seconds and the reasoning shown.

What this means for a practice or a chain:
One visit, one workflow. The screening runs on the station you already have, without a second device.
Referral built in. Send a case to an ophthalmologist for a second opinion without leaving the room.
The same result everywhere. Objective, reproducible outputs across locations, operators and time.

The AI analyses. You decide. RetinaLyze detects signs of pathology; it does not diagnose and does not replace an examination.

If you use the VISUREF 1000 today, book a demo and we will set you up: https://retinalyze.com/free-trial/

12/10/2026

Not every case needs an ophthalmologist. Working out which ones do is the hard part.

In the second film from our cooperation with EYS, Teddy Birch Petersen asks Sondre Enger Beckröge what customers actually need from AI in eye care right now.

His answer is about volume. Patient numbers keep climbing, so the clinical market has to work more efficiently, and sending every case onward to an ophthalmologist isn't efficient. That's where AI fits: fast triage, sorting who genuinely needs a specialist from who doesn't.

He's also direct about the risk. The permanent tension in healthcare is between clinical excellence and efficiency. Technical, regulatory and operational problems can usually be solved. The one to watch is efficiency quietly eating into clinical quality.

And the pressure isn't easing. As populations age, cases of AMD, glaucoma and diabetic retinopathy will keep growing. The underlying need doesn't change. The volume does.

Where do you feel that squeeze most: the quality side or the capacity side?

08/10/2026

Over a billion people still can't get the eye care they need. World Sight Day, on Thursday 8 October, is a yearly reminder that most of that gap is solvable.

The IAPB puts its goal in three words: accessible, available, affordable. For a lot of people in Europe, the most accessible eye care is the optician on their high street. You don't need a referral, and many are open on Saturdays.

That makes it one of the best places to catch disease early, as long as the practice has the right tools. Since 2013, RetinaLyze has analysed fundus photos and OCT scans in optical stores, eye clinics and hospitals. We've now passed 7 million screenings, and a new one finishes about every 35 seconds.

Behind each of those is a person who got a result in around 45 seconds. If something looks wrong, the optometrist can ask an ophthalmologist and send a digital referral without leaving the system.

Software alone won't fix access. Someone still takes the photo, explains the result, and makes sure the referral lands. What it changes is that a proper check no longer depends on having a specialist in the building.

This year's World Sight Day challenge asks people to take eye care into a school, a workplace, or a room where policy is made. We'd add one more place: the shop down the street.

How is your practice marking World Sight Day this year?

06/10/2026

Back from Vienna. One observation, and one thing we got wrong.

The observation: nobody at B60 asked whether AI screening works. Four days, a lot of conversations, not one "does it actually detect anything." Two years ago that was half the questions. The debate has moved to where the result lands, who acts on it, and whether it fits a referral pathway that already exists. That's a healthier debate, and a harder one.

What we got wrong: we came prepared to talk about the AI, and most people wanted to talk about the connection. Topcon Harmony pulling the image from the camera, handing it to RetinaLyze, and putting the answer back in the record without anyone touching a file.

Euretina now has a Special Focus Meeting on AI in retina behind it and another AI event on the calendar for 2027. AI has stopped being a session and started being a line item in a workflow. That suits us. It's the boring part we've been arguing about for years.

Thank you to Topcon Healthcare for the stand and to everyone who stopped, asked awkward questions and stayed for the answer. Same time next year.

Adresse

Lyskær 1
Skovlunde
2730

Åbningstider

Mandag	09:00 - 17:30
Tirsdag	09:00 - 17:30
Onsdag	09:00 - 17:30
Torsdag	09:00 - 17:30
Fredag	09:00 - 17:30

Website

https://retinalyze.com/

Underretninger

Bliv den første, der får besked: Vi sender dig en e-mail, når RetinaLyze International offentliggør nyheder og tilbud. Din e-mailadresse bliver ikke brugt til andre formål, og du kan til enhver tid afmelde dig.